Skip to main content

Table 2 Dose escalation cohort and distribution of patients ( n  = 37)

From: Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

Dose level

Number of patients treated

Azacitidine (mg/m 2 )

Oxaliplatin IV (mg/m 2 /day)

DLT

1

3

20

15

0

2

3

20

22.5

0

3

3

20

30

0

4

3

25

30

0

5

3

40

30

0

6

6

50

30

0

Expansion (dose level 6)

16

50

30

0

  1. DLT, dose-limiting toxicity.